Market Research Logo

Anesthetic Effect - Pipeline Review, H1 2018

Anesthetic Effect - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H1 2018, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 4, 2, 2, 2, 14 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Anesthetic Effect - Overview
Anesthetic Effect - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anesthetic Effect - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anesthetic Effect - Companies Involved in Therapeutics Development
4P Therapeutics LLC
Biolab Farmaceutica Ltda
Crescita Therapeutics Inc
Drawbridge Pharmaceuticals Pty Ltd
Expanesthetics Inc
Jiangsu Hengrui Medicine Co Ltd
Lannett Company Inc
Lee's Pharmaceutical Holdings Ltd
Paion AG
Phosphagenics Ltd
Physica Pharma
Primex Pharmaceuticals Oy
Recro Pharma Inc
The Medicines Company
Anesthetic Effect - Drug Profiles
alphaxalone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aom-0765 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Carboetomidate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cysteine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-09 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Flexicaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSK-3486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine + prilocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methoxycarbonyl Carboetomidate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methoxycarbonyl Etomidate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
midazolam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHY-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Anesthetic Effect - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anesthetic Effect - Dormant Projects
Anesthetic Effect - Discontinued Products
Anesthetic Effect - Product Development Milestones
Featured News & Press Releases
Dec 01, 2017: Lannett Announces FDA Acceptance Of 505(b)(2) New Drug Application For Cocaine Hydrochloride Topical Solution, A Proprietary Anesthetic Product
Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Koera
Nov 09, 2017: Phosphagenics Provides Update on TPM/Propofol Development Program
Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU
Sep 25, 2017: Lannett's Board Of Directors Initiates CEO Search
Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial
Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia
Oct 27, 2016: Lannett Announces Successful Phase III Clinical Trial Results For Proprietary C-Topical Product
Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA
Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Anesthetic Effect, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Anesthetic Effect - Pipeline by 4P Therapeutics LLC, H1 2018
Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H1 2018
Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H1 2018
Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2018
Anesthetic Effect - Pipeline by Expanesthetics Inc, H1 2018
Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Anesthetic Effect - Pipeline by Lannett Company Inc, H1 2018
Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018
Anesthetic Effect - Pipeline by Paion AG, H1 2018
Anesthetic Effect - Pipeline by Phosphagenics Ltd, H1 2018
Anesthetic Effect - Pipeline by Physica Pharma, H1 2018
Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H1 2018
Anesthetic Effect - Pipeline by Recro Pharma Inc, H1 2018
Anesthetic Effect - Pipeline by The Medicines Company, H1 2018
Anesthetic Effect - Dormant Projects, H1 2018
Anesthetic Effect - Dormant Projects, H1 2018 (Contd..1), H1 2018
Anesthetic Effect - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Anesthetic Effect, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report